PGK1 phosphorylates NLRP3 and mediates inflammasome activation independent of its glycolytic activity.

Summary

This study uncovers a non-glycolytic kinase function of PGK1: CK2 phosphorylates PGK1 at S271, switching it to phosphorylate NLRP3 at S448/S449, which recruits USP14 to deubiquitinate and activate the NLRP3 inflammasome. The work provides a mechanistic link between metabolism and innate immune activation, independent of glycolytic flux.

Key Findings

• CK2 phosphorylates PGK1 at S271, serving as a molecular switch for PGK1 kinase function.
• PGK1 phosphorylates NLRP3 at S448/S449, recruiting USP14 to promote NLRP3 deubiquitination and activation.
• PGK1’s regulation of NLRP3 is independent of its glycolytic enzymatic activity and is engaged upon LPS stimulation.

Clinical Implications

While preclinical, this mechanism suggests therapeutic strategies such as inhibiting PGK1’s kinase activity, preventing NLRP3 S448/S449 phosphorylation, or disrupting USP14 recruitment to dampen inflammasome activation in hyperinflammatory states.

Limitations

• Abstract indicates LPS-driven models; extent of in vivo validation in sepsis models and human tissues is not detailed.
• No therapeutic modulation or inhibitor studies are presented to demonstrate druggability.

Future Directions

Test PGK1/NLRP3 phosphorylation blockade in in vivo sepsis models, develop selective PGK1 kinase inhibitors, and validate S271/S448-S449 phosphorylation as biomarkers in human sepsis.